Atherosclerotic vascular events in a multinational inception cohort of systemic lupus erythematosus - sprookjes - yvandenbroek - TriplyDB

Atherosclerotic vascular events in a multinational inception cohort of systemic lupus erythematosus

Atherosclerotic vascular events in a multinational inception cohort of systemic lupus erythematosus

http://www.wikidata.org/entity/Q34338929

about

Vascular disease in systemic lupus erythematosus Miscarriage and future maternal cardiovascular disease: a systematic review and meta-analysis The effect of mycophenolate mofetil on disease development in the gld.apoE (-/-) mouse model of accelerated atherosclerosis and systemic lupus erythematosus Metabolic syndrome is not only a risk factor for cardiovascular diseases in systemic lupus erythematosus but is also associated with cumulative organ damage: a cross-sectional analysis of 311 patients.Use of atorvastatin in systemic lupus erythematosus in children and adolescents Secondary analysis of APPLE study suggests atorvastatin may reduce atherosclerosis progression in pubertal lupus patients with higher C reactive protein.Cardiovascular involvement in autoimmune diseases.Systemic lupus erythematosus and cardiac risk factors: medical record documentation and patient adherence.Presentation of systemic lupus erythematosus (SLE) in emergency department: a case report 25-hydroxyvitamin D and cardiovascular disease in patients with systemic lupus erythematosus: data from a large international inception cohort.IgG anti-apolipoprotein A-1 antibodies in patients with systemic lupus erythematosus are associated with disease activity and corticosteroid therapy: an observational study.Imaging assessment of cardiovascular disease in systemic lupus erythematosus.Autoimmune heart disease: role of sex hormones and autoantibodies in disease pathogenesis Systemic lupus erythematosus in children and adolescents.Effect of Systemic Lupus Erythematosus on the Risk of Incident Respiratory Failure: A National Cohort Study Cardiovascular Events in Systemic Lupus Erythematosus: A Nationwide Study in Spain From the RELESSER Registry.Risk of Peripheral Arterial Occlusive Disease in Patients With Systemic Lupus Erythematosus: A Nationwide Population-Based Cohort Study [Cardiovascular risk factors in systemic lupus erythematosus].Serum Resistin Level and Progression of Atherosclerosis during Glucocorticoid Therapy for Systemic Autoimmune Diseases Cardiovascular disease in latin american patients with systemic lupus erythematosus: a cross-sectional study and a systematic review.Impaired arterial stiffness in systemic lupus ertythematosus - correlations with inflammation markers Epidemiology of CVD in rheumatic disease, with a focus on RA and SLE.The role of antimalarial agents in the treatment of SLE and lupus nephritis.The Systemic Lupus International Collaborating Clinics (SLICC) group - it was 20 years ago today.Utilizing registries in systemic lupus erythematosus clinical research.Transient ischemic attack and stroke in systemic lupus erythematosus.Diagnosis and management of neuropsychiatric SLE.Childhood onset systemic lupus erythematosus: how is it different from adult SLE?Pathogenesis and treatment of atherosclerosis in lupus.Atherosclerotic vascular disease in the autoimmune rheumatologic patient.Why are kids with lupus at an increased risk of cardiovascular disease?Do adverse pregnancy outcomes contribute to accelerated cardiovascular events seen in young women with systemic lupus erythematosus?Stroke in systemic lupus erythematosus and antiphospholipid syndrome: risk factors, clinical manifestations, neuroimaging, and treatment.Update on cardiovascular disease in lupus.Maternal-placental syndrome and future risk of accelerated cardiovascular events in Parous Swedish women with systemic lupus erythematosus - a population-based retrospective cohort study with time-to-event analysis.Peripheral arterial disease in patients with systemic lupus erythematosus: a prospective controlled study.The evolving concept of SLE comorbidities.Incidence and risk of heart failure in systemic lupus erythematosus.Evaluation of mortality, disease activity, treatment, clinical and immunological features of adult and late onset systemic Lupus erythematosus.Survival rates and risk factors for mortality in systemic lupus erythematosus patients in a Chinese center.

P2860

Q21285155-78B6E2F7-6609-4DCE-8F82-B79990E3457F Q24603979-9B0BE3AF-3994-4EBA-817F-F9F027C5A6EC Q28486062-EC35B147-B8E4-4B6E-8268-06E6EF6EEE19 Q33425745-4BC9061D-BE63-46CB-BAA2-5107BC779C36 Q33818710-AF694EEC-F52B-41D0-9B34-B93E3439F106 Q33922922-7FAB90D4-C95E-4056-AA0C-F9814AE22022 Q34081242-D37A9ED9-20C5-4EC8-897E-1E97893FB418 Q34630261-520BF8DD-6A8D-4DB9-9C8E-C13D83C649C0 Q34705015-F3DBA172-85E4-4A15-8474-AAE66079B692 Q35086343-D2B4A6B6-2ECC-4D26-B01D-2D8B706749C2 Q35162593-12792D04-ACB0-48C0-B5D1-BF9A5A6420EB Q35450156-84B5D6CC-2A58-486F-B9FE-3DBCD9A658DB Q35868721-9B3E1799-630D-4E69-87A6-A384F513AA8F Q35947491-C8BCB021-7611-4254-8C84-130BEEE6F9BE Q36139802-BC7A7575-76D1-4A3F-A047-046DD463074A Q36153524-D1A4CAC9-6E1F-41D5-98A8-3F9448EE799C Q36299359-A507390B-36A4-44B9-88A2-F6F2F3285E38 Q36680400-EBEE7780-EC49-417C-B0B9-5F2E87DD8378 Q37294162-E370D306-1159-4C8A-9580-6634918BEB73 Q37330468-EEF45F2A-1117-4EF4-9F9C-4D4205665202 Q37715144-2F700AB7-2BE4-4701-AC84-3E0AF2881627 Q37883018-19AA2A2A-8145-41A9-85D5-BC22699B4BE4 Q37947108-7E2FF6EE-6047-4B27-B019-6EF47E80E9F9 Q37957814-7AC42279-B786-47DC-AC44-F28E7AAD96B5 Q38011226-7E929F26-889A-432C-9E46-B4DCD9DB7A51 Q38149851-FF040090-AC97-4E1E-8B23-320E10567BEB Q38186995-DFF30C1E-39F5-4695-986D-4438300AF17D Q38223293-3FCAF580-0304-4C16-A098-7AF99EF21F93 Q38230699-2D6F35D8-2371-42B9-968F-159FA3FCA170 Q38365624-8B1A0C1C-ACAC-43C4-95F2-3AC57F4380D8 Q38591752-87C01F17-0876-4492-B330-7B38C1B81499 Q38654271-82511BB6-BEF5-4E8B-84EF-FB277A901018 Q38844621-50A4425B-1063-406D-8D92-72B7ADD2DB93 Q38844782-B62BCA01-BA16-46A0-BD6A-70BC19CDE77E Q38889941-05D628A3-FF6C-4A1D-94B3-42C149CC0516 Q39053063-11344D0D-E3B9-498E-A73E-E9E767825180 Q39283399-775DDEF4-1D12-4D68-AB48-C0F430F5BCB3 Q39405417-2ACFB008-F9C1-459E-8852-E1EDAC7DB86D Q43427893-D1F93419-FE2F-4D54-A5C2-6832CDE6CECD Q43468721-A4452EB9-993C-4BFE-A1D3-7DEAF403D749

P2860

Atherosclerotic vascular events in a multinational inception cohort of systemic lupus erythematosus

http://www.wikidata.org/entity/Q34338929

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Atherosclerotic vascular event ...... f systemic lupus erythematosus

@ast

Atherosclerotic vascular event ...... f systemic lupus erythematosus

@en

Atherosclerotic vascular event ...... f systemic lupus erythematosus

@nl

type

label

Atherosclerotic vascular event ...... f systemic lupus erythematosus

@ast

Atherosclerotic vascular event ...... f systemic lupus erythematosus

@en

Atherosclerotic vascular event ...... f systemic lupus erythematosus

@nl

prefLabel

Atherosclerotic vascular event ...... f systemic lupus erythematosus

@ast

Atherosclerotic vascular event ...... f systemic lupus erythematosus

@en

Atherosclerotic vascular event ...... f systemic lupus erythematosus

@nl

P1433

Q34338929-13DBB0FB-D585-4175-BB91-601515C16AC0

P1476

Q34338929-86F504DD-F11E-48A2-966A-D6C5071CF593

P2093

Q34338929-0139963C-3061-405E-8C07-758E40FA2BF2

Q34338929-07B86D19-C0FB-403C-8B7F-8770B756860A

Q34338929-225B2A81-5C46-43F7-9CCD-2D3968CF1A3F

Q34338929-2774CEF2-768F-494E-AC7A-3B98906E0CED

Q34338929-2A9023E3-5E7A-48DD-A4A4-10165F907481

Q34338929-2F81D8D4-CD6E-4D16-9505-399FD6CD7B5C

Q34338929-36E32750-3DC2-40B2-BBFE-59DA3AA4A380

Q34338929-56B126AA-6791-40F6-83D0-7FB296AF3A22

Q34338929-5CCF143E-2D04-4C2B-A3D0-4CF93228109D

Q34338929-5D340D42-ED64-4DE1-ACEC-AB1CE0C8761A

P2860

Q34338929-00E6B136-13C2-4702-9CF1-267F89FFE2F4

Q34338929-0A476B08-DAE2-44AA-9015-359B6377D49C

Q34338929-1392D6B1-9E89-4612-9D2B-D6207882CE20

Q34338929-1BAC4A24-6D72-4A3F-9343-9B118A91CD85

Q34338929-1D2B27CE-FD05-44B2-AB09-635F6F4DB695

Q34338929-37269EDD-ABDC-4DAF-8652-160C273A58D7

Q34338929-5EA90FC3-2345-4F6B-8F04-B95E1B9E9C23

Q34338929-7C34E152-2064-40AD-98D9-8A65F191381D

Q34338929-84C42CAB-16E1-49D7-B497-5D3F3AFDC65F

Q34338929-9DDF0FE0-2AEA-4422-972A-748CBD3E1571

P304

Q34338929-92B1D264-A14D-4207-95CC-5B1994ECAD0B

P31

Q34338929-A98AA797-D8B0-4249-A6FF-22E53ABBE490

P356

Q34338929-2D119648-5918-4E5F-B642-A53AECE75FA5

P433

Q34338929-40911C81-CF08-490A-AD8D-659E8F115AB3

P478

Q34338929-FAD1C429-3F50-4346-A5BC-CC4ECB3C2ABB

P50

Q34338929-3F6CD7C4-FDD0-42A0-9F27-1C37A0672989

Q34338929-5090FEBF-774F-4598-A9E1-9D4368D25805

Q34338929-55581BEF-8591-476C-BD6F-C2DFD212C870

Q34338929-685503E2-25CB-4973-B4AA-0686132E5A62

Q34338929-D1060284-5A2E-4062-92F5-F2914F190A85

Q34338929-DD52F086-BBDE-4FE8-A2DA-E8F7BAD617B5

Q34338929-E01A9319-6BEC-4800-82E8-BCF811707058

P577

Q34338929-A8A3CB3B-E56F-480C-9A85-D4F82024A4BE

P5875

Q34338929-04826193-B6E5-499B-8BA1-AAC7223CED59

P698

Q34338929-6A743489-0280-4AD5-B0FB-DDDD3FB52AF8

P921

Q34338929-6E312619-6394-417A-8A4E-5AE6E62D6538

P932

Q34338929-899100B3-26BD-49E4-B61C-F732677EDAAB

P356

P1433

Arthritis Care and Research

P1476

Atherosclerotic vascular event ...... f systemic lupus erythematosus

@en

P2093

A Clarke

http://www.w3.org/2001/XMLSchema#string

A Rahman

http://www.w3.org/2001/XMLSchema#string

A Zoma

http://www.w3.org/2001/XMLSchema#string

C Aranow

http://www.w3.org/2001/XMLSchema#string

D Ibañez

http://www.w3.org/2001/XMLSchema#string

D J Wallace

http://www.w3.org/2001/XMLSchema#string

E Ginzler

http://www.w3.org/2001/XMLSchema#string

G S Alarcón

http://www.w3.org/2001/XMLSchema#string

G Sturfelt

http://www.w3.org/2001/XMLSchema#string

J G Hanly

http://www.w3.org/2001/XMLSchema#string

P2860

Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus

Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L)

Clinical manifestations and coronary artery disease risk factors at diagnosis of systemic lupus erythematosus: data from an international inception cohort.

Accumulation of coronary artery disease risk factors over three years: data from an international inception cohort.

Changing patterns in mortality and disease outcomes for patients with systemic lupus erythematosus.

Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXIII. Baseline predictors of vascular events.

The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus.

Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus.

Summarizing disease features over time: I. Adjusted mean SLEDAI derivation and application to an index of disease activity in lupus.

Atherosclerotic vascular events in a single large lupus cohort: prevalence and risk factors.

P304

881-887

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/ACR.20122

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

62

http://www.w3.org/2001/XMLSchema#string

P50

Dafna D. Gladman

David A. Isenberg

Caroline Gordon

Michelle A. Petri

Munther A. Khamashta

P577

2010-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44661368

http://www.w3.org/2001/XMLSchema#string

P698

20535799

http://www.w3.org/2001/XMLSchema#string

P921

atherosclerosis

P932

2989413

http://www.w3.org/2001/XMLSchema#string